Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LUFYLLIN vs AMINOPHYLLIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
LUFYLLIN (dyphylline) is a xanthine bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway hyperresponsiveness. It also antagonizes adenosine receptors.
Non-selective phosphodiesterase inhibitor, increasing intracellular c AMP and c GMP; adenosine receptor antagonist, causing bronchodilation, CNS stimulation, and positive chronotropic/inotropic effects.
FDA-approved: Relief and prevention of bronchospasm associated with asthma, chronic bronchitis, and emphysema.,Off-label: Apnea of prematurity, COPD exacerbations.
Treatment of acute bronchial asthma, reversible bronchospasm associated with chronic bronchitis and emphysema,Neonatal apnea (off-label),Adjunctive therapy in COPD exacerbations
200-400 mg orally 3-4 times daily, not to exceed 1600 mg/day. Also available as 200 mg/m L injection, administer 200-400 mg IM or slow IV every 6-8 hours.
Loading dose: 6 mg/kg IV over 30 minutes (if not on theophylline); maintenance: 0.5-0.7 mg/kg/hr IV continuous infusion for adults (non-smoking), higher for smokers (0.7-0.9 mg/kg/hr). Oral: immediate-release 200-400 mg every 6 hours; sustained-release 400-600 mg every 12 hours.
6-8 hours in adults with normal hepatic and renal function. In neonates, half-life is prolonged to 20-30 hours. In patients with hepatic cirrhosis, half-life may extend to 20-30 hours. In congestive heart failure, half-life is prolonged to 12-20 hours.
Terminal elimination half-life: 3–12 hours in adults (mean ~6 hours); prolonged in hepatic impairment, heart failure, or COPD (up to 30 hours); shorter in smokers (4–5 hours due to CYP1A2 induction); neonates: 20–40 hours.
Dyphylline is not metabolized by the liver; it is primarily excreted unchanged by the kidneys. Approximately 80% is eliminated unchanged in urine.
Hepatic demethylation and oxidation via cytochrome P450 isoenzymes (CYP1A2, CYP3A4, CYP2E1); approximately 10% excreted unchanged in urine.
Primarily renal excretion of unchanged drug and metabolites. Approximately 50% is excreted unchanged in urine, with the remainder as metabolites (including 7-hydroxypropyltheophylline and 1,3-dimethyluric acid). Biliary/fecal elimination accounts for <10%.
Renal excretion of unchanged drug accounts for ~10%, with the remainder eliminated as metabolites (caffeine, 3-methylxanthine, 1-methyluric acid, 1,3-dimethyluric acid) via urine; minimal biliary/fecal elimination (<5%).
Approximately 40-50% bound to plasma proteins, primarily albumin.
~40% bound to plasma proteins (primarily albumin).
0.5-0.7 L/kg. This indicates distribution into total body water with some tissue binding.
0.5 L/kg (range 0.3–0.7 L/kg); increased in neonates, cirrhosis, and malnutrition; reflects distribution into total body water.
Oral immediate-release: 90-100%. Rectal: approximately 80-90%. Sustained-release: 70-90% with delayed absorption.
Oral (immediate-release): 100% (well absorbed); rectal: ~80% (variable); IV: 100%.
Cr Cl 30-50 m L/min: administer 50-75% of normal dose. Cr Cl <30 m L/min: administer 25-50% of normal dose. Consider monitoring theophylline levels.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: reduce dose by 25% and monitor levels; GFR <10 m L/min: reduce dose by 50% and monitor levels closely.
Child-Pugh A: no adjustment. Child-Pugh B: administer 50% of normal dose. Child-Pugh C: avoid use or administer 25% of normal dose with close monitoring.
Child-Pugh A: reduce dose by 50%; Child-Pugh B: reduce dose by 75%; Child-Pugh C: use with extreme caution, reduce dose by 90% or consider alternative.
Children <1 year: 100-200 mg/day in 3-4 divided doses. Children 1-9 years: 200-300 mg/day in 3-4 divided doses. Children 9-16 years: 200-400 mg/day in 3-4 divided doses. Weight-based alternative: 10-20 mg/kg/day in 3-4 divided doses.
Loading dose: 5-6 mg/kg IV over 30 minutes (if not on theophylline); maintenance: infants <1 year: 0.4-0.7 mg/kg/hr IV; children 1-9 years: 0.8-1.0 mg/kg/hr IV; children >9 years: 0.6-0.8 mg/kg/hr IV. Oral: immediate-release 5 mg/kg every 6 hours; sustained-release not recommended under 6 years.
Initiate at lower end of dosing range (200 mg 3 times daily). Monitor theophylline levels and adjust dose to maintain trough concentration of 5-15 mcg/m L. Reduce dose if concurrent medications affecting hepatic metabolism.
Reduce maintenance dose by 50-75% compared to younger adults; monitor serum theophylline levels closely; typical starting maintenance: 0.3-0.5 mg/kg/hr IV; avoid doses >400 mg/day oral.
No FDA black box warning.
No specific FDA boxed warning for aminophylline; however, theophylline (its active metabolite) has a narrow therapeutic index and requires serum concentration monitoring to avoid toxicity.
Use with caution in patients with peptic ulcer disease, hyperthyroidism, hypertension, cardiac arrhythmias, or seizure disorders. Monitor serum levels for toxicity. Risk of ventricular arrhythmias or seizures at high doses.
Narrow therapeutic index; monitor serum concentrations (target 10-20 mcg/m L); caution in patients with peptic ulcer, hyperthyroidism, seizure disorders, cardiac arrhythmias; use with drugs that affect CYP1A2 (e.g., cimetidine, fluoroquinolones, fluvoxamine) or induce metabolism (e.g., smoking, rifampin, phenytoin).
Hypersensitivity to dyphylline or any xanthine derivative. Uncontrolled arrhythmias. Active seizure disorder. Severe hypotension. Concurrent use with other xanthines (e.g., theophylline).
Hypersensitivity to aminophylline, theophylline, or ethylenediamine; active peptic ulcer disease; uncontrolled seizure disorders; severe cardiac arrhythmias (unless patient is undergoing monitored treatment).
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they may increase adverse effects like nervousness and palpitations. No significant food interactions other than caffeine. Alcohol may increase CNS stimulation.
High-fat meals can delay absorption of aminophylline. Avoid charred meat and foods containing large amounts of caffeine. Cruciferous vegetables (broccoli, brussels sprouts) may increase metabolism. Maintain consistent dietary intake of protein and carbohydrates as changes can affect theophylline clearance.
Lufyllin (dyphylline) is a xanthine derivative bronchodilator. Animal studies have not demonstrated teratogenicity. Human data are limited; however, as a methylxanthine, risks are considered low. First trimester: No evidence of major malformations. Second and third trimesters: No known fetal harm, but high doses may cause transient neonatal tachycardia or irritability due to placental transfer. Avoid use near term if possible due to potential neonatal effects.
Aminophylline, a theophylline salt, is not teratogenic in humans. First trimester: No increased risk of major malformations. Second trimester: No specific fetal risks; maternal asthma control benefits outweigh risks. Third trimester: Risk of neonatal apnea, irritability, and tachycardia if maternal levels are high; avoid toxic levels.
Dyphylline is excreted into breast milk in small amounts. The milk-to-plasma ratio is approximately 0.7. Estimated infant dose is about 1-2% of maternal weight-adjusted dose. No adverse effects reported in breastfed infants. However, monitor for signs of irritability or sleep disturbances.
Aminophylline is excreted into breast milk; the M/P ratio (milk-to-plasma ratio) is approximately 0.6-0.8. Infant exposure is low (about 1-10% of maternal weight-adjusted dose). Use with caution; monitor infant for irritability and sleep disturbance. Generally considered compatible with breastfeeding.
Pregnancy may alter the pharmacokinetics of methylxanthines due to increased plasma volume and decreased protein binding. However, dyphylline is not extensively protein-bound, so changes may be minimal. No specific dose adjustment is recommended, but monitor clinical response and toxicity. Avoid doses exceeding standard recommendations.
Pregnancy reduces theophylline clearance by 30-50% due to decreased hepatic metabolism and increased volume of distribution. Dose adjustments may be needed: reduce dose by 30% in the third trimester or monitor serum concentrations closely to maintain therapeutic levels (5-15 mcg/m L). Postpartum, clearance returns to prepregnancy levels within 4-6 weeks; readjust accordingly.
Dyphylline (Lufyllin) is a xanthine bronchodilator that is not metabolized to theophylline, making it an alternative for patients who cannot tolerate theophylline. It is 2-3 times less potent than theophylline, requiring higher doses. Renal excretion is the primary elimination route; dose adjustment is needed in renal impairment. Monitor drug interactions with cimetidine, quinolones, and macrolides, though less severe than with theophylline. Use with caution in patients with peptic ulcer, hyperthyroidism, or seizure disorders. Therapeutic levels are not well-defined, but target 6-18 mcg/m L for theophylline equivalents.
Aminophylline is a bronchodilator composed of theophylline and ethylenediamine. The ethylenediamine component can cause hypersensitivity reactions. Monitor theophylline serum levels (target 10-20 mcg/m L). Use with caution in patients with cardiac arrhythmias, seizures, or peptic ulcer disease. Avoid in patients with porphyria. Cimetidine, ciprofloxacin, and macrolides can increase theophylline levels. Smoking induces metabolism, requiring higher doses.
Take this medication exactly as prescribed, do not double doses if missed.,Avoid excessive caffeine intake (coffee, tea, cola, chocolate) as it may increase side effects.,Report any signs of toxicity such as nausea, vomiting, insomnia, anxiety, or palpitations.,Do not crush or chew extended-release tablets unless instructed.,Maintain adequate hydration to help prevent side effects.,Inform your doctor if you are pregnant, breastfeeding, or have liver, kidney, or heart disease.
Take this medication exactly as prescribed, with or without food.,Do not crush or chew extended-release formulations.,Avoid consuming large amounts of caffeine (coffee, tea, chocolate, energy drinks) as it may increase side effects.,Report symptoms such as rapid heart rate, persistent nausea/vomiting, insomnia, or seizures immediately.,Do not stop abruptly without consulting your doctor.,Keep a regular dosing schedule to maintain consistent blood levels.
No interactions on record
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LUFYLLIN vs AMINOPHYLLIN, answered by our medical review team.
LUFYLLIN is a Xanthine Bronchodilator that works by LUFYLLIN (dyphylline) is a xanthine bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway hyperresponsiveness. It also antagonizes adenosine receptors.. AMINOPHYLLIN is a Xanthine Bronchodilator that works by Non-selective phosphodiesterase inhibitor, increasing intracellular c AMP and c GMP; adenosine receptor antagonist, causing bronchodilation, CNS stimulation, and positive chronotropic/inotropic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LUFYLLIN and AMINOPHYLLIN depend on the specific clinical indication. These are both Xanthine Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LUFYLLIN is: 200-400 mg orally 3-4 times daily, not to exceed 1600 mg/day. Also available as 200 mg/m L injection, administer 200-400 mg IM or slow IV every 6-8 hours.. The standard adult dose of AMINOPHYLLIN is: Loading dose: 6 mg/kg IV over 30 minutes (if not on theophylline); maintenance: 0.5-0.7 mg/kg/hr IV continuous infusion for adults (non-smoking), higher for smokers (0.7-0.9 mg/kg/hr). Oral: immediate-release 200-400 mg every 6 hours; sustained-release 400-600 mg every 12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LUFYLLIN and AMINOPHYLLIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LUFYLLIN is classified as Category C. Lufyllin (dyphylline) is a xanthine derivative bronchodilator. Animal studies have not demonstrated teratogenicity. Human data are limited; however, as a methylxanthine, risks are . AMINOPHYLLIN is classified as Category C. Aminophylline, a theophylline salt, is not teratogenic in humans. First trimester: No increased risk of major malformations. Second trimester: No specific fetal risks; maternal ast. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.